Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Biotech Partners to Develop, Offer Alzheimer's Disease Tests
News Update

Share on Stocktwits


ProMIS Neurosciences and its collaborator make their relationship official with a joint venture agreement.

ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) partnered with BC Neuroimmunology Lab (BCNL) to develop and offer highly accurate, objective tests for Alzheimer's disease detection, diagnosis and monitoring, it announced in a news release.

"We now have blood-based biomarkers that can provide the information necessary to detect Alzheimer's disease, including pre-symptomatic disease. Measurable Alzheimer's neuropathology precedes cognitive decline by 15-20 years, and this represents an invaluable window of opportunity for prevention, and prevention begins with detection. ProMIS' ultimate mission with its partner BCNI is to build a portfolio of assays that enables early detection and monitoring of disease progression before symptoms arise," ProMIS Executive Chairman Eugene Williams said in the release.

In that regard, ProMIS and BCNL formed a revenue-sharing joint venture. These collaborators intend to start by offering blood-based assays for the two brain protein biomarkers, neurofilament light chain (NfL) and phosphorylated tau181 (P-tau181).

"The progress this year in measuring P-tau181 in the blood marks an inflection point in the fight against Alzheimer's disease," added Williams.

"We know that lifestyle interventions like diet, exercise and mental stimulation can have a significant impact on progression to cognitive decline," said Dr. Sharon Cohen, director of the Toronto Memory Program. "What has been missing prior to the recent advent of blood-based biomarkers is a convenient and accurate way to measure the impact of these interventions in pre-symptomatic patients. ProMIS' exciting work with blood-based biomarkers for the detection and monitoring of AD could potentially contribute to a breakthrough in how we work with our patients to prevent Alzheimer's disease."


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS Neurosciences, a company mentioned in this article.

Want to read more about Life Sciences Tools & Diagnostics investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe